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Key points 
• Secondary iron overload is common in lower-risk MDS patients and is associated with 
morbidity and mortality 
• Iron Chelation Therapy may improve overall survival and hematopoiesis in lower-risk MDS 
patients 
  
Abstract 
Iron overload due to red blood cell transfusions is associated with morbidity and mortality in lower-
risk myelodysplastic syndrome patients. Many studies suggested improved survival after iron 
chelation therapy, but valid data are limited. The aim of this study was to assess the effect of iron 
chelation on overall survival and hematological improvement in lower-risk myelodysplastic syndrome 
patients in the European MDS registry. We compared chelated patients with a contemporary, non-
chelated control group within the European MDS registry, that met the eligibility criteria for starting 
iron chelation. A Cox proportional hazards model was used to assess overall survival, treating receipt 
of chelation as a time-varying variable. Additionally, chelated and non-chelated patients were 
compared using a propensity-score matched model. Of 2200 patients, 224 received iron chelation. 
The hazard ratio and 95% confidence interval for overall survival for chelated patients, adjusted for 
age, sex, comorbidity, performance status, cumulative red blood cell transfusions, IPSS-R, and 
presence of ringed sideroblasts was 0.50 (0.34-0.74). The propensity-score analysis, matched for age, 
sex, country, red blood cell transfusion intensity, ferritin level, comorbidity, performance status, and 
IPSS-R and additionally corrected for cumulative red blood cell transfusions and presence of ringed 
sideroblasts, demonstrated a significantly improved overall survival for chelated patients with a 
hazard ratio of 0.42 (0.27-0.63) compared to non-chelated patients. Up to 39% of chelated patients 
reached an erythroid response. In conclusion, our results suggest that iron chelation may improve 
overall survival and hematopoiesis in transfused lower-risk myelodysplastic syndrome patients.  
This trial was registered at www.clinicaltrials.gov as #NCT00600860. 
  
Introduction  
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic stem 
cell disorders characterized by abnormal differentiation and maturation of hematopoietic cells, bone 
marrow failure and genetic instability, with an enhanced risk of progressing to acute myeloid 
leukemia.
1 
Iron overload, as a consequence of frequently administered red blood cell transfusions 
(RBCT) and/or ineffective erythropoiesis, is a common finding in MDS. The effects of toxic iron 
species in other iron loading diseases, such as primary hemochromatosis, thalassemia and sickle cell 
anemia are well known, but the consequences in MDS are less clear.
2-4
 With an expected median 
survival of 2.4 to 11.8 years in lower risk MDS (LR-MDS) patients
5
 these patients are prone to long-
term accumulation of iron due to RBCT as well as direct iron toxicity due to the formation of reactive 
oxygen species (ROS).
6 
Several studies have reported beneficial effects of iron chelation therapy (ICT) on overall survival (OS) 
and other clinical outcomes in MDS patients with iron overload.
7-10
 However, valid data on the effect 
of ICT are limited as most studies are executed in small or highly selected patient groups or suffer 
from serious methodological problems such as confounding by indication. Performing a randomized, 
controlled trial for this research question is cumbersome due to a widespread belief of patients in 
the beneficial effects of ICT and additionally, the personal opinion on ICT of many treating physicians, 
which may negatively affect enrollment. Likewise, patients included in a randomized, controlled trial 
do not generally reflect the actual LR-MDS patient group, which are usually elderly patients with 
multiple comorbidities. 
In addition to the possible beneficial effects of iron chelation therapy on overall survival, increasing 
evidence indicates hematological improvement in patients during treatment with iron chelators.
11-16
 
Next to improvement in hemoglobin, platelet, and neutrophil levels, transfusion independency is 
achieved in a minority of chelated patients.
11,12,14
 The underlying mechanisms are still unclear.
17 
The aim of this study was to evaluate the effect of iron chelation therapy on OS, hematological 
improvement, and ferritin levels in lower risk MDS patients in the EUMDS Registry.
 
 
 
 
 
 
 
Methods 
The EUMDS registry prospectively collects observational data on LR-MDS patients from 142 centers 
in 16 countries in Europe and Israel. Patients were included within 100 days of MDS diagnosis 
according to the World Health Organization 2001 classification, restricted to patients with a low or 
intermediate-1 score according to the international prognostic scoring system (IPSS).
18
 IPSS was the 
current prognostic indicator at the start of the registry, in accordance with the currently used 
prognostic score, the revised IPSS (IPSS-R) was reconstructed afterwards. The ethics committees of 
all participating centers approved the protocol and all patients provided written informed consent. 
Data were collected at baseline and at each 6-monthly outpatient routine follow-up visit. Data were 
collected on: comorbidity, transfusion history, use of iron chelators (agent, time frame; no drug 
doses or schedules were collected), peripheral blood values, conventional iron parameters (e.g. 
serum ferritin), bone marrow pathology, and progression to higher-risk MDS or acute myeloid 
leukemia. Subjects were prospectively followed until death, loss to follow-up, or withdrawal of 
informed consent.  
In Europe, three iron chelators are available for treatment of secondary iron overload, but availability 
varies between countries. We analyzed all patients, chelated or non-chelated, who are eligible for 
receiving ICT based on at least one criterion for starting ICT (cumulative ≥15 RBC units, RBCT intensity 
of ≥1 unit/month during a six-month period, or serum ferritin level >1000 µg/L), thereby preventing 
immortal time bias. As chelated and non-chelated patients may differ in characteristics that affect 
outcome, two different approaches were performed in order to control for potential bias: 1) Analysis 
of all eligible chelated and non-chelated patients using receipt of ICT as a time-varying covariate; 
adjusting for covariates related to both ICT receipt and OS: sex, age, comorbidity, performance 
status, RBCT intensity, number of units transfused, IPSS-R, and presence of ringed sideroblasts; 2) 
Propensity score (PS), i.e. conditional probability for being treated with ICT on basis of patient 
characteristics, matching of the same group. Variables included in the PS were: age, sex, country, 
RBCT intensity, ferritin level, MDS comorbidity index, performance status, and IPSS-R. A 3-to-1 
nearest neighbor matching method with replacement and caliper (0.2) was applied.
19
 Additionally, 
we used a robust sandwich estimator to correct for intra-individual correlation of multiply used 
controls. Further details on the PS matching are provided in the supplementary methods.
20-22 
OS was 
defined as the time from eligibility for ICT to death; subjects still alive were censored at the last 
follow-up date. Cox proportional hazards regression models and Kaplan-Meier survival curves were 
applied and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were reported.
23
  
Erythroid responses were defined as a reduction in RBCT density (number of RBCT over time, see 
supplementary methods for definition and details) or as transfusion independency at least once as 
the transfusion density was reduced to zero, platelet responses were assessed according to the 
modified international working group (IWG) criteria.
24
 Ferritin responses were defined as a decrease 
of ≥1000 µg/L or a drop of the serum ferritin value below 1000 µg/L.  
All analyses were undertaken in Stata 15 (StataCorp, College Station, TX).  
 
Results 
Patient population 
Data were extracted from the EUMDS registry on July 5, 2017, 2,200 patients, diagnosed between 
December 3, 2007 and April 25, 2017, had been registered, of which 1,161 patients received at least 
one RBCT and 224 patients received iron chelation therapy (ICT) (figure 1). A small proportion of 
patients had received ICT without being transfused or prior to starting RBCT, these subjects generally 
had a high ferritin level and were excluded from subsequent analyses. Of the 1,161 transfused 
patients, 850 patients had been transfused for a duration of ≥2 months. Out of these 850 patients, 
689 met the eligibility criteria. Supplementary figure 1 summarizes the number of patients who 
reached each criterion. At the time of analysis, 236 patients were deceased (154 non-chelated, 82 
chelated) and nine patients progressed to high-risk MDS or AML (4 non-chelated, 5 chelated). 
 
Comparing outcome of chelated versus non-chelated patients using ICT as a time-dependent variable 
Table 1 shows the characteristics of the 689 patients who met one of the eligibility criteria at the visit 
prior to meeting one of the eligibility criteria; the date of this visit is when the patients enter this 
analysis. The mean age of the 199 chelated patients was 70 years and these patients were younger 
than the non-chelated patients whose mean age was 76 years. Median time from date of diagnosis 
to date of meeting the eligibility criteria was seven months in the non-chelated and eight months in 
the chelated subjects. The median follow-up period from study entry for chelated and non-chelated 
patients was 39.4 months (range 4.1 – 106.6) and 27.1 months (range 2.5 – 105.6), respectively. Non-
chelated subjects had a higher number of cumulative units transfused than chelated subjects (4 vs 2 
units) at time of inclusion and, on average, chelated patients had 13 units transfused prior to 
commencing ICT. The latter had a higher median ferritin level recorded at baseline (675 µg/L vs 547 
µg/L), and this had increased to 1,221 µg/L prior to start of ICT. Whilst non-chelated and chelated 
subjects had similar IPPS-R scores, chelated patients had fewer co-morbidities as measured by the 
MDS-CI score and a better performance status as measured by Karnofsky performance status. Overall 
survival was estimated using receipt of ICT as a time-dependent variable – hence the number of 
patients reported in the risk table in Figure 2 reflects the time when a subject commences ICT. The 
hazard ratio for overall survival in the univariate analysis was 0.57 (95% CI: 0.45-0.73) (Figure 2, Table 
1). This benefit increased when adjusted for the factors in Table 1 and the following variables: sex, 
RBCT intensity, and the presence of ringed sideroblasts (HR: 0.50, 95% CI: 0.34-0.74). No statistically 
significant interactions were detected by using a sophisticated prediction-type model. When we 
restricted the analysis to patients who were treated with deferasirox (the largest group), thereby 
excluding possible differences between patients using different chelators, the crude HR for OS was 
0.53 (95% CI: 0.40-0.69) and the adjusted HR for OS was 0.38 (95% CI: 0.24-0.60). Out of the 199 
chelated patients, 150 received deferasirox as the initial chelator, 36 deferoxamine, and 13 
deferiprone, and differences were seen in the baseline characteristics by type of chelator with 
deferasirox treated patients being younger and fitter. Twenty-two patients switched from one 
chelator to another, or were treated with all three chelators consecutively (Supplementary Table 1), 
but usually the treatment period of the second chelator was shorter than the treatment period of the 
first chelator. The median time on chelation for all 199 patients was 13 months (range 3-41 months) 
and patients who were initially treated with deferoxamine had inferior overall survival compared to 
deferasirox treated patients (Table 1: adjusted HR: 2.46, 95% CI: 1.12-5.41). The overall survival of 
deferoxamine-treated patients was similar to non-chelated patients (adjusted HR: 0.98, 95% CI: 0.52-
1.86). 
 
Matching of chelated and non-chelated patients by propensity scores 
The variables used in the propensity score matching are described in supplementary table 2 for all 
eligible patients by chelation status; initially excluding any missing variables and then after multiple 
imputation (MI). Along with factors already shown in table 1, there was a difference by country as to 
whether a patient was treated with ICT; patients in the UK were less likely to be treated.  
The overlap of propensity scores of both groups (chelated and non-chelated), which is essential for 
PS matching, was good for the majority of the patients (Supplementary figure 2). The matched MI 
dataset included 197/199 chelated cases and identified 591 non-chelated controls. There were no 
differences by sex, RBCT intensity, cumulative RBCT units, serum ferritin levels, comorbidity, 
performance status, IPSS-R, presence of ringed sideroblasts, quality of life (QoL), and country 
between both groups (Table 2). Figure 3 shows the unadjusted survival plot by ICT status with receipt 
of ICT as a time-dependent variable for the matched patients. A multivariate Cox proportional hazard 
model was used to adjust for potential confounders (age, sex, comorbidity, performance status, 
monthly RBCT intensity, number of RBC units transfused, IPSS-R, and presence of ringed 
sideroblasts). The estimated crude and adjusted hazard ratios were 0.70 (95% CI: 0.51-0.95) and 0.42 
(0.27-0.63), respectively (Table 2) and the adjusted survival curve is shown in Figure 4. When we 
again restricted the analysis to the deferasirox treated patients, the crude HR for OS was 0.63 (95% 
CI: 0.45-0.88) and the adjusted HR was 0.34 (95% CI: 0.22-0.53). 
The distribution of ESA and lenalidomide-treated patients among chelated and non-chelated patients 
at time of eligibility were similar in the unmatched and matched sample. A sensitivity analysis 
excluding the treatment of ESA and lenalidomide showed similar results.  
 
Impact of iron chelation therapy on hematopoiesis and ferritin levels 
Figure 5 shows the changes in transfusion density over eight visits in chelated and non-chelated 
patients. Forty-eight (62.3%) of the 77 responding patients were treated with ESA and 16 (20.8%) 
were treated lenalidomide during chelation therapy. Compared to visit 1, 61 of the 197 chelated 
patients (31.0%) had a reduction in transfusion density, i.e. an absolute decrease, during at least one 
visit interval, 2 patients (1.0%) maintained the same density throughout, and 134 (68.0%) never had 
a reduction in transfusion density. For those patients who showed a reduction, the average value in 
the monthly rate was -1.63 units per month (SD: 2.12, median: -0.96) compared to visit 1. Figure 6A 
shows the monthly red blood cell transfusion density for chelated patients with and without an 
erythroid response and non-chelated patients. In terms of becoming transfusion independent, 35 
(17.8%) of the 197 treated patients had at least one visit interval during, approximately six months, 
which they had not received any further transfusions and 19 (9.6%) of the 197 patients were 
transfusion independent during more than one visit interval after starting chelation therapy. In total, 
54 patients (27.4%) became (temporarily) transfusion independent.  
In total, 77 chelated patients had an erythroid response: 61 patients had a reduction in transfusion 
density, and 16 patients who did not have a reduction in transfusion density became transfusion 
independent during at least one visit interval. We observed hematological responses with all 
chelating agents. 
A subgroup of chelated patients had a platelet response (22.9%) at least temporary over time. 
Median platelet counts were in the normal range in both the chelated and non-chelated group. 
Figure 6B demonstrates ferritin levels of chelated patients with and without a ferritin response and 
non-chelated patients. Fifteen (51.7%) of the 29 responding patients were treated with ESA and 5 
(17.2%) were treated with lenalidomide. A subgroup of patients had a ferritin response (5.6-23.5%) 
over time. Responding patients showed ongoing mean serum ferritin levels around 1000 µg/L, 
whereas non-responding chelated patients had mean ferritin values around 2100 µ/L. 
 
Follow-up chelated patients 
On average, chelated patients did not start therapy until 17 months after diagnosis (Table 1). Of the 
199 chelated patients, at the time of the analysis, follow-up was ongoing for 148 patients, for seven 
patients their disease had progressed to higher risk MDS/AML, 29 patients had died, and 4 have 
missing values of treatment dates (those four patients are still ongoing), 9 patients had withdrawn 
from the study (four of these because of disease progression and five after starting intensive 
treatment like an allogeneic stem cell transplantation), and 6 were lost to follow-up. Most patients 
(101 of the 148 ongoing patients) were receiving chelation at the time of the last report. Twenty of 
the 199 chelated patients switched from deferasirox to another chelating agent. 
 
Reasons for cessation of iron chelation therapy 
Information on reasons of cessation of ICT was not routinely recorded in the study, however, 
information about the deferasirox-treated patients was available for 7 patients: fatigue and 
diarrhoea (1 patient), physician’s choice (1 patient), economic reasons (1 patient), renal failure (1 
patient), no effect (1 patient), dyspepsia (1 patient) and lower limb cramps and dosage change (1 
patient).  
Renal function 
Non-chelated patients had slightly higher median creatinine values compared to chelated patients at 
time of eligibility (non-chelated: median 86 µmol/L [p10-p90: 61-135]; chelated: median 79 µmol/L 
[p10-p90: 59-107]). Forty-four chelated patients had higher serum creatinine levels at the first visit 
after discontinuing chelation compared with creatinine levels at time of eligibility (p=0.02 for all 
chelating agents and p=0.03 for deferasiox-treated patients),  
Renal function in non-chelated patients increased similarly over time (Figure 7). 
 
Discussion 
The results of this study indicate that iron chelation therapy (ICT) may improve OS in transfusion 
dependent lower risk MDS patients (LR-MDS). Our results are in line with several previously reported 
studies.
7-10,12,25-28
 Some of these studies attempted to correct for confounding factors, but still 
suffered from confounding by indication. This generally results in an overestimation of the beneficial 
effect of ICT on OS in LR-MDS patients. Currently, one randomized controlled trial has been reported 
on this subject. The randomized, placebo-controlled, TELESTO trial
29
 evaluated the event-free 
survival (EFS) (a composite outcome, including non-fatal events related to cardiac and liver function, 
and transformation to acute myeloid leukemia or death) and safety of deferasirox versus placebo in 
low and intermediate-1-risk MDS patients. This study demonstrated an EFS risk reduction of 36.4% in 
the deferasirox arm (p=0.015). However, the median overall survival in the deferasirox-treated arm 
was not different (HR 0.83, 95% CI 0.54-1.28, P=0.200) when compared with placebo, but more than 
50% of the placebo-treated patients switched to ICT after study treatment discontinuation (the 
placebo drug). The results of the TELESTO study are in line with our results, however, the included 
patients may not represent ‘real life’ elderly MDS patients with multiple comorbidities, as reflected 
by the mean age of 61 years old of the patients included in TELESTO study compared to the mean 
age of 70 years in the EUMDS Registry study. Furthermore, low accrual rates and the cross-over to 
ICT after cessation of the placebo, affected the statistical power of the TELESTO study. 
Meanwhile, well-designed prospective observational data, reflecting, ‘real life’ data, contribute to 
the better understanding of the effect of ICT on OS in LR-MDS patients. Recently, a study from the 
Canadian MDS registry demonstrated a superior OS for 83 chelated patients compared to non-
chelated patients (5.2 vs. 2.1 years, p<0.001).
30
 The patients in this study were selected at the onset 
of transfusion-dependency. Chelated patients became transfusion-dependent at a much longer 
interval from diagnosis than non-chelated patients (median 18 versus 6 months) and OS was 
calculated from the time of becoming transfusion-dependent. Even after matching, some 
incomparability between the two groups remained in factors like concurrent treatment, presence of 
ringed sideroblasts, and ferritin levels. Therefore, confounding cannot be excluded in this study. 
Nevertheless, their conclusions are in accordance with our findings, supporting the probable 
beneficial effect of iron chelation therapy on OS in LR-MDS patients.  
The mechanisms by which iron chelation therapy influences OS after a relatively short exposure to 
iron chelation therapy (median duration of 13 months) is not completely understood. A recently 
published study of the EUMDS Registry, as well as the follow-up data of this study, demonstrated 
detectable labile plasma iron (LPI) levels to be associated with inferior overall survival in LR-MDS 
patients.
31,32 
The risk of dying prematurely in patients with detectable LPI levels occurred too early in 
this study to explain this risk by classical iron overload due to organ toxicity (e.g. liver and heart) after 
long-term transfusions, but this indicates a direct toxic effect associated with elevated LPI levels.
31
  
Likewise, increasing evidence supports that increased LPI levels may be a general predictor of an 
increased non-relapse mortality during and after hematopoietic stem cell transplantion.
33
  
Toxic iron species are known to catalyze the cellular generation of reactive oxygen species (ROS), 
which play a key role in cellular damage.
34,35
 ROS damage (mitochondrial) DNA, with potential 
consequent genomic instability, mutagenesis, and cell death. ROS are associated with leukemic 
transformation of the MDS clone.
6
 Moreover, iron chelation therapy is associated with a decrease of 
LPI and ROS.
6,16
 Overall, the present study indicates that iron chelation therapy may partly counteract 
the unfavorable consequences of secondary iron overload. 
 
In up to 31.0% of chelated patients a reduction in transfusion density was observed during at least 
one visit interval. Likewise, 27.4% of the responding patients became, at least temporarily, 
transfusion independent. Platelet responses were less frequently observed. However, platelet count 
in this context was less relevant because the platelet counts in both groups were within the normal 
range, and will not likely lead to severe bleeding complications. Contemporary treatment with ESA 
and/or lenalidomide may have enhanced these responses. 
Several previous studies recorded hematological responses to ICT.
11-16
 While the percentage of 
patients with hematological responses in these studies are in line with the present study, none of the 
former studies included a control group in their analyses. One of the factors playing a role is the 
relatively short period of ICT (median 13 months) in this study. The duration of ICT may improve by 
the introduction of a better tolerated formulation of deferasirox.
36
 Usually, ICT is prescribed 
relatively late after detection of signs of iron overload. Earlier initiation of ICT may prevent or 
decrease the occurrence of transfusional iron toxicity on hematopoiesis. Moreover, we recorded 
data only at six monthly intervals. Short duration hematological responses in between visits may be 
missed by this approach. But on the other hand, short-lasting responses may not be clinically 
relevant. 
Preclinical studies have shown a beneficial effect of ICT on hematopoiesis.
35,37
 Inhibition of the 
transcription factor NF-ĸB, involved in many cellular processes, and modulation of mammalian target 
of rapamycin (M-TOR) signaling, a major regulator of cell death and proliferation, have been 
proposed to play a role.
17
 Future studies should address this issue appropriately. 
 
In the trajectory analyses, ferritin responses occurred in up to 23.5% of the chelated patients. Serum 
ferritin levels have been reported frequently as a prognostic marker in LR-MDS patients, but serum 
ferritin is an imprecise surrogate marker for secondary iron overload and toxicity.
38,39
 This is reflected 
by the observation that a relatively small proportion of chelated patients have a considerable 
decrease in serum ferritin levels, while these patients show a significant survival benefit. Serum 
ferritin levels are influenced by the stage of MDS and by concurrent infection and inflammation, 
which is common in LR-MDS patients.
38
 Additionally, no convincing evidence exists regarding its use 
for monitoring secondary IO in MDS patients.
38,40
 Currently, tissue biopsy and MRI T2* are regarded 
as most specific and sensitive diagnostic tests for detecting IO.
38
 However, the clinical utility of these 
assays remains unclear in MDS and invasiveness (biopsy), unavailability, and expense (MRI T2*) 
hampers their general use in clinical practice. LPI, as discussed above, is associated with inferior 
survival in LR-MDS patients.
31,32 
Future studies are warranted to evaluate the effect of ICT on LPI 
levels as a measure of iron toxicity. Also measures of oxidative stress, including malondialdehyde, a 
long-lasting lipid peroxidation product, formed as a consequence of oxidative stress from iron 
overload, are possible future markers for detecting and monitoring of the biological consequences of 
secondary IO in LR-MDS patients, should they be proven to correlate with clinical outcomes.
41,42 
Analysis of renal function demonstrated that iron chelation therapy is associated with an increase of 
creatinine levels. In some patients this will be clinically relevant and/or a reason to stop or lower the 
dose of iron chelation therapy. In other patients an increase in creatinine levels will not affect 
cessation of iron chelation therapy.  
 
 
Strengths and limitations 
This large cohort, with prospectively collected ‘real life’ data from diagnosis, provides an unique 
opportunity to study the effect of iron chelation therapy in a large number of lower-risk MDS 
patients in daily practice. An important strength is that the results are widely generalizable to this, 
mostly elderly, patient population with multiple comorbidities, who are typically excluded from 
clinical trials. The variation in iron chelation practice across the different countries, due to variable 
interpretation of the poor quality outcome data for ICT in MDS, made it possible to compare the 
effects of ICT on OS to a non-chelated control group. In Europe, unlike in the United States, socio-
economic status does not influence the prescription of ICT (either deferoxamine or deferasirox) 
because the costs are covered by the health insurance systems. 
Since conventional statistical modeling is limited by the number of covariates to be added to a 
model, propensity-score matched analysis is able to incorporate more confounding factors in the 
model, including country-specific effects. Confounding by indication, a common problem in 
observational studies, is maximally reduced by using the propensity-score matched method and 
therefore a major strength of this study. To our knowledge, we are the first to apply this method in 
order to adequately deal with confounding in this setting. 
Limitations of our study include the moderate sample size of the deferoxamine and deferiprone 
groups. Additionally, differences in dosing schemes and therapy compliance could not be considered 
in our analysis. This prevented us from drawing definitive conclusions of the effect of the separate 
iron chelators on OS. Data were collected at the scheduled 6-monthly intervals. Subtle changes in 
patient-related factors in the intervening 6-month period may have been missed. Not all patients can 
be matched by the propensity score approach. This might introduce selection bias. However, the 
same magnitude and direction of the results were seen in the analysis of the unmatched samples. 
Therefore, in this case, propensity-score matching will probably not have led to significant selection 
bias. Finally, despite using a large control group, eligible for using iron chelation therapy, and a 
propensity-score matched analysis corrected for many known and measured confounders, we cannot 
exclude residual confounding. Considering the size of the effect, it is unlikely that residual 
confounding would explain the difference found between chelated and non-chelated patients.  
In summary, the results of this study suggest that iron chelation therapy may improve OS and 
hematopoiesis in transfused LR-MDS patients. 
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Table 1: Baseline characteristics of non-chelated and chelated patients at the visit prior to reaching the eligibility criteria and estimates of overall survival. 
Non-chelated Chelated Deferasirox Deferoxamine Deferiprone 
Total 490 199 150 36 13 
No. of countries with chelated patients 17  /  17 17  /  17 14  /  17 9  /  17 6  /  17 
Mean age at eligible (SD) 76   (10) 70   (9) 70   (9) 72   (9) 70   (10) 
Time from diagnosis (months) 
Inclusion, median (p10-p90)         7   (0 - 35)        8   (0 - 32)        9   (0 - 36)       6   (0 - 30)        7   (0 - 33) 
Inclusion, mean (SD) 14   (16) 13   (15) 14   (16)  9   (11) 12   (13) 
Chelation median (p10-p90) NA      17   (4 - 46)      17   (4 - 47)      13   (2 - 39)      22   (5 - 51) 
Chelation mean (SD) NA 21   (17) 21   (18) 17   (13) 26   (18) 
Number of units transfused 
Median (range) 4.0   (1.0 – 33.0)   2.0   (0.0 – 28.0)   2.5   (0.0 – 28.0)   3.0   (0.0 – 18.0) 2.0   (0.0 – 8.0) 
Median at start of chelation (range) NA 13.0   (2.0 – 91.0) 12.0   (2.0 – 75.0) 10.5   (2.0 – 75.0) 24.5   (2.0 – 91.0) 
Ferritin (µg/L) 
Median (p10-p90) 547.0   (116.0 – 1384.0)   675.0   (256.0 – 1573.0)   683.0   (264.0 – 1600.0)   682.0   (256.0 – 1920.0) 525.0   (190.5 – 918.1) 
Median at start of chelation (p10-p90) NA 1221.0   (475.8 – 3000.0) 1210.0   (449.3 – 2832.0) 1173.0   (335.0 – 3000.0) 2202.0   (475.8 – 4900.0) 
Comorbidity (MDSCI) 
Low risk 308   63.2% 150   75.8% 118   79.2% 23   63.9%   9   69.2% 
Intermediate risk 149   30.6%   43   21.7%   28   18.8% 11   30.6%   4   30.8% 
High risk 30   6.2%   5   2.5%   3   2.0% 2   5.6% 0   0.0% 
Performance status 
Unable to care for self   8   2.0%   1   0.6%   1   0.8% 0   0.0% 0   0.0% 
Unable to work 132   32.3%   36   20.2%   21   15.9% 12   34.3%   3   27.3% 
Able to work and normal activity 269   65.8% 141   79.2% 110   83.3% 23   65.7%   8   72.7% 
Prognostic indicator (IPSS-R) 
Reaching criteria (LOCF***) 
Very low   48   13.4%   22   13.5%   18   14.6% 2   6.9%   2   18.2% 
Low 199   55.6%   95   58.3%   66   53.7% 21   72.4%   8   72.7% 
Intermediate 111   31.0%   46   28.2%   39   31.7%   6   20.7% 1   9.1% 
High   38   10.6%   9   5.5%   6   4.9%   3   10.3% 0   0.0% 
Very high   3   0.8%   1   0.6%   1   0.8% 0   0.0% 0   0.0% 
Duration of treatment with chelation (months)  
Median (p10-p90) NA 13   (3 - 41) 14   (3 - 41) 9   (1 - 34) 13   (2 - 30) 
Ever received ESAs 
No 312   63.7% 115   57.8%   85   56.7%   22   61.1%   8   61.5% 
Yes 178   36.3%   84   42.2%   65   43.3%   14   38.9%   5   38.5% 
Ever received hypomethylating 
No 460   93.9% 184   92.5% 136   90.7%   36   100.0% 12   92.3% 
Yes 30   6.1% 15   7.5% 14   9.3%   0   0.0% 1   7.7% 
Ever received lenalidomide 
No 467   95.3% 179   89.9% 136   90.7%   33   91.7% 10   76.9% 
Yes 23   4.7%   20   10.1% 14   9.3%   3   8.3%   3   23.1% 
Overall Survival (OS)* 
Unadjusted 1 0.57   (0.45 – 0.73) 1 1.99   (1.18 – 3.35) 0.42   (0.10 – 1.71) 
Adjusted** 1 0.50   (0.34 – 0.74) 1 2.46  (1.12 – 5.41) 0.30   (0.02 – 3.58) 
* HRs and 95% CI were estimated using receipt of chelation as a time-varying covariate 
** adjusted by age at eligibility criteria, sex, comorbidity, performance status, number of units transfused, IPSS-R, and ringed sideroblasts present 
*** LOCF: last observation carried forward (only for cytogenetics and bone marrow blasts) 
SD: standard deviation; RBCT: red blood cell transfusion; MDSCI: myelodysplastic syndrome specific comorbidity index; IPSS-R: revised international prognostic scoring system 
 
Table 2  Baseline characteristics for all matched subjects included in the propensity analyses 
 
Covariates 
Matched* data with imputations** 
Non-chelated Chelated P-Value 
Standardized 
differences*** 
N = 591 N = 197 
Age (years) 71    (11) 70    (9) 0.364 -0.077 
Sex 0.797 -0.021 
Female 210    35.5% 72    36.5% 
Male 381   64.5% 125   63.5% 
RBCT Intensity (per month) 0.7   (1.0) 0.6   (1.0) 0.484 -0.058 
Cumulative RBCT units 4.5   (4.9) 4.3   (4.7) 0.570 -0.047 
Ferritin level (µg/L, median, p25-p75) 730.6   (494.6-977.3) 683.6   (504-915.5) 0.328 -0.086 
Comorbidity (MDSCI) 0.965 -0.004 
Low risk 440   74.5% 150   76.1% 
Intermediate risk 145   24.5%   42   21.3% 
High risk   6   1.0%   5   2.5% 
Performance status 0.279 0.090 
Unable to care for self   4   0.7%   1   0.5% 
Unable to work 135   22.8%   38   19.3% 
Able to work and normal activity 452   76.5% 158   80.2% 
Prognostic indicator (IPSS-R) 0.914 0.009 
Very low   83   14.0%   22   11.2% 
Low 337   57.0% 120   60.9% 
Intermediate 134   22.7%   45   22.8% 
High 34   5.8%   9   4.6% 
Very high   3   0.5%   1   0.5% 
Ring-sideroblast present 0.445 0.062 
Yes 419   70.9% 134   68.0% 
No 172   29.1%   63   32.0% 
Platelet level (10^9/L, median, p25-p75) 162.5   (99.2-294) 224.0   (121-324) 0.086 0.148 
Haemoglobin level (g/dL, median, p25-p75) 8.8   (8.2-9.8)   8.4   (7.7-9.5) 0.021 -0.194 
Quality of Life (EQ-5D) 
Index (mean, SD) 0.7   (0.2) 0.7   (0.2) 0.186 0.125 
VAS (mean, SD) 64.8   (21.0) 68.1   (19.9) 0.083 0.165 
Country 0.140 -0.122 
Austria 25   4.2% 10   5.1% 
Croatia  9   1.5%  1   0.5% 
Czech Republic 58   9.8%  25   12.7% 
Denmark 15   2.5%  8   4.1% 
France 113   19.1%  40   20.3% 
Germany 23   3.9%  8   4.1% 
Greece  80   13.5%  23   11.7% 
Israel 11   1.9%  5   2.5% 
Italy 11   1.9%  5   2.5% 
Netherlands 17   2.9%  7   3.6% 
Poland 22   3.7%  8   4.1% 
Portugal  2   0.3%  1   0.5% 
Romania 34   5.8% 11   5.6% 
Republic of Serbia  8   1.4%  2   1.0% 
Spain 11   1.9%  5   2.5% 
Sweden  97   16.4%  20   10.2% 
UK 55   9.3% 18   9.1% 
Overall Survival (OS) 
Unadjusted 1.0 0.70  (0.51 – 0.95) 
Adjusted**** 1.0 0.42   (0.27 – 0.63) 
Note: Continuous variables are reported as mean (standard deviation), while categorical variables are reported as number 
(percent) 
* Matched by age, gender, country, RBCT intensity, ferritin level, comorbidity, performance status, and IPSS-R at eligibility 
** Multiple imputations in RBCT intensity, ferritin level, comorbidity, performance status, and IPSS-R at eligibility for non-
chelated patients 
*** The standardized difference in percent is the mean difference as a percentage of the average standard deviation 
**** Adjusted by age, sex, comorbidity, performance status, RBCT intensity, number of units transfused, IPSS-R, and RS 
present 
RBCT: red blood cell transfusion; MDSCI: myelodysplastic syndrome specific comorbidity index; IPSS-R: revised international 
prognostic scoring system; EQ-5D: European Quality of Life - 5 dimensions 
 
Figure 1 Number of registry patients by transfusion and chelation status. 
 
Number of registry patients by transfusion and chelation status. 
RBCT = Red Blood Cell Transfusion  
*Cumulative RBCT units >=15 or RBCT intensity of ≥1 RBC unit/month or Serum Ferritin >1000 µg/L.  
 
 
Figure 2 Overall Survival by Iron Chelation Therapy (ICT) as a Time-Dependent Variable in unmatched 
patients. 
 
Figure 3 Overall Survival by Iron Chelation Therapy (ICT)
 
as a Time-Dependent Variable in matched 
patients. 
 
Figure 4 Adjusted Overall Survival by Iron Chelation Therapy (ICT)
 
as a Time-Dependent Variable in 
matched patients. 
 
Figure 5 Changes in transfusion density over time in chelated and non-chelated patients. 
Legend 5:  
time: eight 6-monthly visits 
 
Figure 6 Trajectory analysis in chelated patients with and without response and for non-chelated 
patients. 
Legend figure 6: 
6A: Monthly red blood cell transfusion density for chelated patients with and without an erythroid 
response and for non-chelated patients. 6B: Ferritin levels of patients with and without a ferritin 
response, defined as a decrease of ≥1000 µg/L or a drop of the serum ferritin value below 1000 µg/L, 
and for non-chelated patients. 
 
Figure 7 Serum creatinine levels (µmol/L) in chelated and non-chelated patients per visit. 
 







Supplementary Material 
 
Supplementary Method Section 
General 
In the EUMDS registry, clinical information was collected via a bespoke web-based database on: 
concomitant diseases, transfusion history, use of iron chelators (chelating agent, start date and end 
date; no drug doses or schedules were collected), peripheral blood values, conventional iron 
parameters (serum ferritin, transferrin saturation), concomitant treatments (lenalidomide, erythroid 
stimulating agents [ESA], and hypomethylating therapy), and bone marrow pathology.   
As information is recorded at 6-monthly time-points and the patients may have reached the criteria 
for using iron chelation therapy between visits, the visit prior to reaching the criteria was selected.  
Propensity score matched method  
The main purpose of PSM was to balance the distribution of observed covariates at the time of 
meeting the eligibility criteria in both the chelated and non-chelated groups, so there should be no 
systematic differences in the distribution and overlap of covariates between the two groups after 
matching.
20
 The causal effect of ICT on outcome was estimated in two stages. In the first stage, the 
propensity score (PS) or the conditional probability of receiving ICT among eligible subjects were 
estimated using multivariate logistic regression using the characteristics below, identified a priori to 
be involved in the decision to treat a patient with ICT; A PS graph was used to check visually if the 
common support condition was satisfied, i.e. if there was sufficient overlap.
21
 To examine the 
balance in this study, we computed standardized differences that were defined as the difference 
between chelated and non-chelated means of each factor, divided by the pooled standard deviation. 
Absolute values of standardized differences <0.1 indicated sufficient balance.
20
 A p-value of 0.01 or 
lower was considered to be statistically significant. 
Missing data in PS estimations could result in biased estimates, and it may also shrink the pool of 
potential matches. The following methods were used to impute missing values: 1) last observation 
carried forward (LOCF) approach: For many patients bone marrow assessments were not repeated 
after initial diagnosis, accordingly karyotype and bone marrow blast count, required for the 
calculation of the IPSS-R at each visit, may be missing. A LOCF approach for only these two 
components of the IPSS-R was applied; 2) Multiple imputation (MI) approach: For missing values of 
RBCT intensity, serum ferritin level, MDS comorbidity index, Karnofsky performance status, and IPSS-
R, a MI approach was applied to create 20 multiple complete data sets consisting of all non-chelated 
patients and all visits since the last visit prior to meeting the eligibility criteria.
22
 The imputation 
model also included age, sex, and cumulative RBCT units. 
Transfusion dose density 
We used the beginning of the time interval in which the first transfusion started after diagnosis as 
the starting point of time to calculate the cumulative number of transfusion units received and time 
interval by the end of each subsequent visit. Transfusion dose density was calculated by dividing the 
cumulative number of units by the time since the starting time point and standardised to monthly 
value.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary tables 
Supplementary Table 1 Description of iron chelator use 
 Unmatched Sample Matched      Sample 
  N % N % 
No iron chelation 490 71.12 591 75.00 
Deferasirox only 135 19.59 134 17.01 
Deferoxamine only 30 4.35 29 3.68 
Deferiprone only 12 1.74 12 1.52 
Deferasirox and deferoxamine 13 1.89 13 1.65 
Deferasirox and deferiprone 4 0.58 4 0.51 
Deferoxamine and deferiprone 2 0.29 2 0.25 
All of the three 3 0.44 3 0.38 
Total 689 100 461 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary table 2 Baseline characteristics for all unmatched transfused non-chelated and 
chelated patients with missing values and imputed values 
 
 
 
 
 
 
 
 
 
 
 
N= 490 N= 199 N= 490 N= 199
Age (years) 76 (10) 70 (9) 76 (10) 70 (9)
Sex
Female 194 39,6% 72 36,2% 194 39,6% 72 36,2%
Male 296 60,4% 127 63,8% 296 60,4% 127 63,8%
RBCT Intensity (per month) 0,5 (0,8) 0,6 (1,0) 0,5 (0,8) 0,6 (1,0)
Ferritin level (ug/L, median, p25-p75) 547,0 (251.2-878.8) 675,0 (434.9-992) 693,5 (382-884) 685,8 (504-921)
Comorbidity (MDSCI)
Low risk 308 63,2% 150 75,8% 309 63,1% 151 75,9%
Intermediate risk 149 30,6% 43 21,7% 151 30,8% 43 21,6%
High risk 30 6,2% 5 2,5% 30 6,1% 5 2,5%
Performance status
Unable to care for self 8 2,0% 1 0,6% 8 1,6% 1 0,5%
Unable to work 132 32,3% 36 20,2% 151 30,8% 39 19,6%
Able to work and normal activity 269 65,8% 141 79,2% 331 67,6% 159 79,9%
Prognostic indicator (IPSS-R)
Very low 48 12,0% 22 12,7% 49 10,0% 22 11,1%
Low 199 49,9% 95 54,9% 276 56,3% 121 61,1%
Intermediate 111 27,8% 46 26,6% 124 25,3% 45 22,7%
High 38 9,5% 9 5,2% 38 7,8% 9 4,5%
Very high 3 0,8% 1 0,6% 3 0,6% 1 0,5%
Country
Austria 22 4,5% 10 5,0% 22 4,5% 10 5,0%
Croatia 3 0,6% 1 0,5% 3 0,6% 1 0,5%
Czech Republic 39 8,0% 25 12,6% 39 8,0% 25 12,6%
Denmark 24 4,9% 8 4,0% 24 4,9% 8 4,0%
France 88 18,0% 40 20,1% 88 18,0% 40 20,1%
Germany 7 1,4% 8 4,0% 7 1,4% 8 4,0%
Greece 34 6,9% 23 11,6% 34 6,9% 23 11,6%
Israel 20 4,1% 5 2,5% 20 4,1% 5 2,5%
Italy 19 3,9% 5 2,5% 19 3,9% 5 2,5%
Netherlands 10 2,0% 8 4,0% 10 2,0% 8 4,0%
Poland 15 3,1% 9 4,5% 15 3,1% 9 4,5%
Portugal 15 3,1% 1 0,5% 15 3,1% 1 0,5%
Romania 11 2,2% 11 5,5% 11 2,2% 11 5,5%
Republic of Serbia 7 1,4% 2 1,0% 7 1,4% 2 1,0%
Spain 32 6,5% 5 2,5% 32 6,5% 5 2,5%
Sweden 34 6,9% 20 10,1% 34 6,9% 20 10,1%
UK 110 22,4% 18 9,0% 110 22,4% 18 9,0%
Covariates
Unmatched data with missing values Unmatched data with imputations*
Non-chelated Chelated
P -Value
Standardise
d 
Non-chelated Chelated
P -Value
Standardised 
differences**
0,038 0,169 0,046 0,161
-0,554 0,000 -0,554
0,405 0,070 0,405 0,070
0,000
0,046 0,204 0,152 0,124
0,001 -0,291 0,001 -0,296
0,001 0,313 0,001 0,290
0,001 -0,283 0,001 -0,283
0,138 -0,137 0,106 -0,139
RBCT: red blood cell transfusion; MDSCI: myelodysplastic syndrome specific comorbidity index; IPSS-R: revised international prognostic scoring system; EQ-5D: European Quality 
of Life - 5 dimensions
Note: Continuous variables are reported as mean (standard deviation), while categorical variables are reported as number(percent)
* Multiple imputations in RBCT intensity, ferritin level, comorbidity, performance status, and IPSS-R at eligibility criteria for unchelated patients
** The standardised difference in percent is the the mean difference as a percentage of the average standard deviation
*** Adjusted by age, sex, comorbidity, performance status, RBCT intensity, number of units transfused, IPSS-R, and RS present
Supplementary figures 
Supplementary figure 1 Proportion of subjects meeting the eligibility criteria (n=689) 
 
RBCT = Red Blood Cell Transfusion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary figure 2 Overlap of propensity scores for the chelated and non-chelated groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
